What this means
This trial plans to check if a new shingles vaccine is safe and triggers an immune response in healthy adults. No results have been posted, so we do not yet know how it works.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 40 and over
- Where
- Not listed
The science
- Registered title
- Safety and Immunogenicity of SYS6017 in Healthy Participants Aged 40 Years or More
- Trial ID
- NCT06954818 ↗
- Phase
- PHASE 1
- Study type
- interventional
- Conditions
- Herpes Zoster
- What is tested
- A zoster mRNA vaccine SYS6017, Placebo
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
- Ages
- 40 Years to no maximum
- Dates
- First posted May 2, 2025 · updated May 8, 2025
Registry summary
Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging. Vaccination plays a key role in reducing the disease burden of zoster and the associated complications. This randomized, observer-blind, placebo-controlled, adaptive phase 1 trial aims to evaluate the safety and immunogenicity of an investigational zoster mRNA vaccine in healthy participants aged 40 years or more.